AUTHORS
Shuhua Yi, DO, Tingyu of Wang2, Fei Li, MD, PhD3, Yanping Ma, MD4, Xingli Zou5, Keshu Zhou, PhD6, Jingdong Zhang7, Lu-Gui Qiu, PhD8
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology Blood Diseases Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology Blood Diseases Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Tianjin, China
3 Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
4 Second Hospital of Shanxi Medical University, Taiyuan, China
5 Affiliated Hospital of North Sichuan Medical college, Nanchong, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Zhengzhou, China
7 Ganzhou People's Hospital, Ganzhou, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology Blood Diseases Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Tianjin, China
ABSTRACT
Introduction
The combination of venetoclax and ibrutinib has demonstrated efficacy in the first-line treatment of CLL/SLL. However, the efficacy and safety profile of this regimen indicates a need for a more potent and tolerable combination of BTK and BCL2 inhibitors. Additionally, questions remain regarding the optimal duration of therapy. Minimal residual disease (MRD) is at the center of this exploration. Previous studies suggest the potential for finite treatment according to MRD status in patients with treatment-naïve (TN) CLL/SLL.
Sonrotoclax, a next-generation BCL2 inhibitor, is a more selective and more pharmacologically potent inhibitor of BCL2 than venetoclax (Liu et al. Blood. 2024).
To explore a novel BTK and BCL2 inhibitors combination, as well as the role of MRD-guided finite therapy duration, this study is designed to evaluate the efficacy and safety of sonrotoclax plus zanubrutinib with MRD-guided treatment duration as frontline therapy for patients with CLL/SLL. Herein, we reported the preliminary results.
Methods
This was a prospective, multicenter, single-arm, phase II study. Eligible patients were previously untreated CLL/SLL that require treatment per 2018 iwCLL criteria, ≤75 years old, an ECOG performance score of 0 to 2, and adequate hematologic and organ function. Patients received 3 cycles of zanubrutinib lead-in (160 mg BID, every 28 days per cycle) to mitigate risk of tumor lysis syndrome (TLS). After the zanubrutinib lead-in, sonrotoclax would be added with a ramp-up schedule to the intended target dosage of 320 mg QD at a 28-day cycle. The combination of sonrotoclax and zanubrutinib would be continued for up to 2 years, unless the stopping rules are reached, or until disease progression or unacceptable toxic effects occurred. Patients would be assessed at the end of cycle 12 (EOT1) and cycle 24 (EOT2) of combination treatment to determine if they met the stopping rules. The stopping rules are defined as uMRD4 (undetectable MRD at <10-4 sensitivity) in both peripheral blood (PB) and bone marrow (BM) as assessed by flow cytometry at EOT1 or EOT2, along with clinical response of at least PR. For subjects who did not meet the stopping rules till EOT2, zanubrutinib monotherapy would be administered till PD or intolerance.
The primary endpoint was 4-year PFS rate. Secondary endpoints included complete response rate (CRR), defined as CR or CR with incomplete hematopoietic recovery (CRi); ORR; duration of response; rates of uMRD4 in BM and PB by EOT1 and EOT2; PFS; overall survival; time to next therapy; safety and tolerability.
Results
From Jul 2024 to May 2026, 69 patients were enrolled. Overall, the median age was 59.0 (range: 32, 76) years and 63.8% were male. At baseline, 60.3% (35/58) of patients had unmutated IGHV, and 20.9% (14/67) had TP53 mutation or del(17p).
As of 15 May 2026, 54 patients were efficacy evaluable. With a median follow up of 12.2 (range:3.2, 22.4) months, ORR was 92.6% (50/54) and 40.7% (22/54) patients achieved CR/CRi. Among these patients, 13 patients have completed 12 cycles of combination treatment achieving an ORR of 100% (8 CR, 3 CRi and 2 partial response) and were assessed for MRD status. The uMRD4 rate was both 76.9% (10/13) in BM and PB at EOT1. Of 3 patients with positive MRD, 1 patient only received zanubrutinib plus sonrotoclax at full dose for 99 days during the first-year combination treatment, and the other patient had two abnormal cell populations at baseline which one abnormal cell population remained after 1 year combination treatment.
The incidences of treatment emergent adverse events (TEAE) at any grade and grade ≥3 were 66.7% and 23.2%, respectively. Serious adverse events were 10.1%. The most common TEAE were mainly hematologic toxicities including decreased neutrophil count (any grade, 33.3%; grade ≥3, 17.4%), decreased white blood cell count (any grade, 24.6%; grade ≥3, 2.9%) and decreased platelet count (any grade, 10.1%; grade ≥3, 0%). No TLS was observed.
Conclusions
The preliminary results showed that zanubrutinib in combination with sonrotoclax had promising efficacy, with high ORR of 100% after 12 cycles of treatment in previously untreated patients with CLL/SLL. The regimen has a favorable safety profile. The study is ongoing and updated results will be released continuously.
DISCLOSURES
Shuhua Yi, DO: No relevant conflicts of interest to declare.